|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Tumor xenograft models were created to detect the role of MIAT in vivo tumorigenesis.
|
31404776 |
2019 |
|
Myocardial Infarction
|
0.500 |
Biomarker
|
disease |
BEFREE |
Myocardial infarction associated transcript (MIAT) is identified as lncRNAs, which is involved in various diseases, pathological and physiological processes, such as myocardial infarction, diabetic retinopathy, paranoid schizophrenia, microvascular dysfunction and formation of nuclear bodies, and neurogenic commitment.
|
26707210 |
2016 |
|
Chronic Chagas' disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Myocardial Infarction-Associated Transcript, a Long Noncoding RNA, Is Overexpressed During Dilated Cardiomyopathy Due to Chronic Chagas Disease.
|
26951817 |
2016 |
|
Myocardial Infarction
|
0.500 |
Biomarker
|
disease |
BEFREE |
MIAT, originally isolated as a candidate gene for myocardial infarction, encodes lncRNA (termed MIAT).
|
27527866 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MIAT expression level was further determined in chronic lymphocytic leukemias (CLL), characterized by expansion of leukemic cells with mature B phenotype, to demonstrate relatively high occurrence of MIAT upregulation in aggressive form of CLL carrying either 17p-deletion, 11q-deletion, or Trisomy 12 over indolent form carrying 13p-deletion.
|
27527866 |
2016 |
|
Diabetic Cardiomyopathies
|
0.010 |
Biomarker
|
disease |
BEFREE |
lncRNA MIAT functions as a competing endogenous RNA to upregulate DAPK2 by sponging miR-22-3p in diabetic cardiomyopathy.
|
28703801 |
2017 |
|
Arteriosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
MIAT facilitated cell proliferation, accelerated cell cycle progression and inhibited apoptosis in ox-LDL-induced AS cell lines, while this effect was partly reversed by miR-181b overexpression.
|
29136944 |
2018 |
|
Atherosclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
MIAT facilitated cell proliferation, accelerated cell cycle progression and inhibited apoptosis in ox-LDL-induced AS cell lines, while this effect was partly reversed by miR-181b overexpression.
|
29136944 |
2018 |
|
MIXED LINEAGE LEUKEMIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
MIAT silencing impeded the binding of MLL on the matrix metalloproteinase 9 (MMP9) promoter region and epigenetically reduced MMP9 transcriptional activity.
|
29228680 |
2017 |
|
Myocardial Infarction
|
0.500 |
Biomarker
|
disease |
BEFREE |
MIAT originally has been considered as an lncRNA to be associated with a susceptibility to myocardial infarction.
|
29345338 |
2018 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
MIAT expression was much higher in high-grade tumors compared to low-grade ones.
|
29345338 |
2018 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
LncRNA MIAT expression was associated with tumor size, lymph node metastasis, distant metastasis and TNM stage.
|
29487526 |
2018 |
|
Hyperactive behavior
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
MIAT interacted with miR-34a and epigenetically controlled the miR-34a expression by hyper-methylating its promotor.
|
29487526 |
2018 |
|
Myocardial Infarction
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Myocardial infarction associated transcript (MIAT), which was recently found to demonstrate aberrant expression in various diseases, such as myocardial infarction, schizophrenia, ischemic stroke, diabetic complications, age-related cataract and cancers, is a novel disease-related lncRNA.
|
29534728 |
2018 |
|
Malignant Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Myocardial infarction associated transcript (MIAT), which was recently found to demonstrate aberrant expression in various diseases, such as myocardial infarction, schizophrenia, ischemic stroke, diabetic complications, age-related cataract and cancers, is a novel disease-related lncRNA.
|
29534728 |
2018 |
|
Secondary malignant neoplasm of lymph node
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
MIAT was highly expressed in GC tissues and cell lines and correlated with differentiation degree, TNM stage, distant metastasis, and lymph node metastasis.
|
29540201 |
2018 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
MIAT knockdown inhibited GC growth and metastasis both in vitro and in vivo.
|
29540201 |
2018 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
MIAT knockdown inhibited GC growth and metastasis both in vitro and in vivo.
|
29540201 |
2018 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MIAT knockdown inhibited GC growth and metastasis both in vitro and in vivo.
|
29540201 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MIAT knockdown inhibited proliferation, migration and invasion and enhanced apoptosis of CRC cells.
|
29686537 |
2018 |
|
Pancreatic carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MIAT expression was found remarkably increased and miR-133 expression was significantly decreased in PC tissues and PC cell lines (PATU-8988, BxPC-3, PANC-1, SW1990 and AsPC-1 cells).
|
29772434 |
2018 |
|
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MIAT expression was found remarkably increased and miR-133 expression was significantly decreased in PC tissues and PC cell lines (PATU-8988, BxPC-3, PANC-1, SW1990 and AsPC-1 cells).
|
29772434 |
2018 |
|
Oestrogen receptor positive breast cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MIAT was over-expressed in ER-positive breast cancer tissues and ER-positive breast cancer cell line MCF-7.
|
29792859 |
2018 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
MIAT is a long noncoding RNA (lncRNA) involved in cell proliferation and the development of tumor.
|
30041179 |
2018 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
MIAT was up-regulated in ccRCC tissues and cell lines.
|
30041179 |
2018 |